Antiproliferative effect of methyl-m-cyclodextrin in vitro and in human tumour xenografted athymic nude mice
1998

Antiproliferative Effect of Methyl-β-Cyclodextrin in Cancer Treatment

Sample size: 24 publication Evidence: moderate

Author Information

Author(s): PY Grosse, F Bressolle, F Pinguet

Primary Institution: Val d'Aurelle Anticancer Center, Montpellier, France

Hypothesis

Can methyl-β-cyclodextrin (MEBCD) effectively reduce tumor growth in human cancer models compared to doxorubicin?

Conclusion

Methyl-β-cyclodextrin significantly reduced tumor volume in both MCF7 and A2780 cancer models without notable toxicity.

Supporting Evidence

  • MEBCD reduced tumor volume by at least twofold compared to control groups.
  • MEBCD was more effective than doxorubicin in the MCF7 model.
  • No significant toxicity was observed in mice treated with MEBCD.

Takeaway

Methyl-β-cyclodextrin can help shrink tumors in mice without making them sick, which is good news for cancer treatment.

Methodology

In vitro and in vivo studies were conducted using MCF7 and A2780 cancer cell lines and xenografted mice, with MEBCD administered at varying doses.

Limitations

The study was limited to specific cancer cell lines and animal models, which may not fully represent human responses.

Participant Demographics

Female Swiss nude mice aged 5 weeks and weighing 20-22 g were used for the in vivo studies.

Statistical Information

P-Value

<0.01

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication